ALNY
Price
$481.46
Change
+$0.39 (+0.08%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
63.06B
6 days until earnings call
RARE
Price
$32.64
Change
-$1.33 (-3.92%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
3.27B
18 days until earnings call
Interact to see
Advertisement

ALNY vs RARE

Header iconALNY vs RARE Comparison
Open Charts ALNY vs RAREBanner chart's image
Alnylam Pharmaceuticals
Price$481.46
Change+$0.39 (+0.08%)
Volume$12.28K
Capitalization63.06B
Ultragenyx Pharmaceutical
Price$32.64
Change-$1.33 (-3.92%)
Volume$30.22K
Capitalization3.27B
ALNY vs RARE Comparison Chart in %
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. RARE commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (ALNY: $481.07 vs. RARE: $33.97)
Brand notoriety: ALNY and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 84% vs. RARE: 132%
Market capitalization -- ALNY: $63.06B vs. RARE: $3.27B
ALNY [@Biotechnology] is valued at $63.06B. RARE’s [@Biotechnology] market capitalization is $3.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • ALNY’s TA Score: 4 bullish, 4 bearish.
  • RARE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ALNY and RARE are a good buy in the short-term.

Price Growth

ALNY (@Biotechnology) experienced а +5.28% price change this week, while RARE (@Biotechnology) price change was +7.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +16.02%, and the average quarterly price growth was +79.42%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($63.1B) has a higher market cap than RARE($3.27B). ALNY YTD gains are higher at: 104.441 vs. RARE (-19.254). ALNY has higher annual earnings (EBITDA): -170.84M vs. RARE (-435.33M). ALNY has more cash in the bank: 2.86B vs. RARE (477M). RARE has less debt than ALNY: RARE (36.3M) vs ALNY (1.3B). ALNY has higher revenues than RARE: ALNY (2.46B) vs RARE (610M).
ALNYRAREALNY / RARE
Capitalization63.1B3.27B1,927%
EBITDA-170.84M-435.33M39%
Gain YTD104.441-19.254-542%
P/E RatioN/AN/A-
Revenue2.46B610M404%
Total Cash2.86B477M599%
Total Debt1.3B36.3M3,573%
FUNDAMENTALS RATINGS
ALNY vs RARE: Fundamental Ratings
ALNY
RARE
OUTLOOK RATING
1..100
2516
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
7100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9792
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (65) in the Biotechnology industry is in the same range as ALNY (95). This means that RARE’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (7) in the Biotechnology industry is significantly better than the same rating for RARE (100). This means that ALNY’s stock grew significantly faster than RARE’s over the last 12 months.

ALNY's SMR Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that ALNY’s stock grew similarly to RARE’s over the last 12 months.

RARE's Price Growth Rating (92) in the Biotechnology industry is in the same range as ALNY (97). This means that RARE’s stock grew similarly to ALNY’s over the last 12 months.

RARE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALNY (100). This means that RARE’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYRARE
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 12 days ago
63%
Bearish Trend 11 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIBLX30.44-0.03
-0.10%
Touchstone Balanced Y
RPMGX101.90-0.55
-0.54%
T. Rowe Price Mid-Cap Growth
APSGX17.37-0.16
-0.91%
NYLI Fiera SMID Growth Class I
JSVTX15.90-0.18
-1.12%
Janus Henderson Small-Mid Cap Value T
PLKGX88.86-1.44
-1.59%
Putnam Small Cap Growth R6

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with IONS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
+2.30%
IONS - ALNY
47%
Loosely correlated
+0.94%
ARGX - ALNY
42%
Loosely correlated
+2.66%
SGMO - ALNY
42%
Loosely correlated
-6.54%
AXSM - ALNY
39%
Loosely correlated
-3.53%
RARE - ALNY
37%
Loosely correlated
+1.62%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+1.62%
MREO - RARE
71%
Closely correlated
-0.99%
NRIX - RARE
49%
Loosely correlated
-3.09%
IONS - RARE
48%
Loosely correlated
+0.94%
NUVL - RARE
47%
Loosely correlated
+0.87%
TRDA - RARE
47%
Loosely correlated
-0.16%
More